Lead Product(s) : Modified Vaccinia Virus Ankara, Live
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bavarian Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents
Details : Imvanex (modified vaccinia ankara) is a non-replicating approved vaccine, which is being evaluated for the treatment of small pox and mpox in adolescents 12 to 17 years of age.
Product Name : Imvanex
Product Type : Vaccine
Upfront Cash : Inapplicable
August 16, 2024
Lead Product(s) : Modified Vaccinia Virus Ankara, Live
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBS-NN/NN2,Aluminum,GBS-NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : EQT Life Sciences
Deal Size : $56.8 million
Deal Type : Financing
Details : This financing will enable MinervaX to progress its novel GBS vaccine GBS-NN/NN2, towards Phase III clinical trials in 2024. The Company is currently progressing two Phase II clinical trials in 470 pregnant persons across Denmark, United Kingdom, Uganda ...
Product Name : GBS-NN/NN2
Product Type : Vaccine
Upfront Cash : Undisclosed
November 10, 2023
Lead Product(s) : GBS-NN/NN2,Aluminum,GBS-NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : EQT Life Sciences
Deal Size : $56.8 million
Deal Type : Financing
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The process is designed to facilitate the development of investigational treatment GBS-NN/NN2, that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.
Product Name : GBS-NN/NN2
Product Type : Vaccine
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : REPAIR Impact Fund
Deal Size : $23.4 million
Deal Type : Financing
Details : The GBS-NN/NN2 vaccine consists of two fusion proteins consisting of either AlpCN and RibN (GBS-NN) or Alp1N and Alp2/3N (GBS-NN2), formulated with AlOH adjuvant.
Product Name : GBS-NN/NN2
Product Type : Vaccine
Upfront Cash : Undisclosed
December 15, 2022
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : REPAIR Impact Fund
Deal Size : $23.4 million
Deal Type : Financing
Lead Product(s) : ABNCoV2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate
Details : Data from topline results from Phase 2 trial demonstrated that cVLP-RBD (ABNCoV2) can boost neutralizing antibodies to levels reported to be highly efficacious against SARS-CoV2, irrespective of type of vaccine previously received, or initial level of ne...
Product Name : ABNCoV2
Product Type : Vaccine
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : ABNCoV2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABNCoV2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from the remaining two groups are now available, confirming the ability of cVLP-RBD (ABNCoV2) to boost neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-2.
Product Name : ABNCoV2
Product Type : Vaccine
Upfront Cash : Inapplicable
February 28, 2022
Lead Product(s) : ABNCoV2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olitigaltin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients treated with GB0139 had a significantly greater rate of decline in oxygen requirement versus standard of care alone and showed other signs of reduced organ damage.
Product Name : GB0139
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : Olitigaltin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABNCoV2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine
Details : ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac using their proprietary capsid virus like particle (cVLP) technology.
Product Name : ABNCoV2
Product Type : Vaccine
Upfront Cash : Inapplicable
August 23, 2021
Lead Product(s) : ABNCoV2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBS-NN
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MinervaX Provides Clinical and Leadership Update
Details : Group B Streptococcal vaccine based on traditional capsular polysaccharide (CPS) conjugate technology consists of two fusion proteins consisting of either AlpCN and RibN (GBS-NN) or Alp1N and Alp2/3N (GBS-NN2), formulated with AlOH adjuvant.
Product Name : GBS-NN
Product Type : Vaccine
Upfront Cash : Inapplicable
July 10, 2021
Lead Product(s) : GBS-NN
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MVA-BN
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company reported that MVA-BN RSV had met its primary endpoint in a Phase 2 human challenge study, demonstrating a statistically significant reduction in viral load in vaccinated versus control treated volunteers.
Product Name : MVA-BN
Product Type : Vaccine
Upfront Cash : Inapplicable
June 12, 2021
Lead Product(s) : MVA-BN
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable